-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Polatuzumab vedotin (PoV) has recently shown promise in the treatment of patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in combination with rituximab-bendamustine (BR) Active
Polatuzumab vedotin (PoV) has recently shown promise in the treatment of patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in combination with rituximab-bendamustine (BR) Active
Therefore, a foreign research team conducted an experiment to evaluate the efficacy and safety of PoV-based chemotherapy (including schemes other than BR) as the third-line or beyond treatment for R/R DLBCL patients, and to explore prognostic factors
Therefore, a foreign research team conducted an experiment to evaluate the efficacy and safety of PoV-based chemotherapy (including schemes other than BR) as the third-line or beyond treatment for R/R DLBCL patients, and to explore prognostic factors
The team recruited a total of 40 patients, including 37 new-onset patients and 3 transformed DLBCL
Figure 1: A: Overall survival rate of 40 patients with relapsed/refractory DLBCL using pov-based treatment
Figure 2: Prognosis study based on pov treatment
Figure 2: Prognosis study based on pov treatment
In addition, normal lactate dehydrogenase levels and absolute lymphocyte count/absolute monocyte count ratio> 1.
In addition, normal lactate dehydrogenase levels and absolute lymphocyte count/absolute monocyte count ratio> 1.
Table: Safety analysis of pov-based treatment for R/RDLBCL patients Table: Safety analysis of pov-based treatment for R/RDLBCL patients
In conclusion, this experiment proved that PoV combined with BR or other intensive chemotherapy is an effective and well-tolerated rescue option for patients with R/R DLBCL
In conclusion, this experiment proved that PoV combined with BR or other intensive chemotherapy is an effective and well-tolerated rescue option for patients with R/R DLBCL
Original source:
Wang, YW.
Wang, YW.
, Tsai, X.
CH.
, Hou, HA.
et al.
Polatuzumab vedotin--based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience.
Ann Hematol (2021).
https://doi.
org/10.
1007/s00277-021-04711-9
Leave a message here
